Dr Lal PathLabs, a major diagnostic operator based in Delhi, reported a 27.5% year-on-year growth in consolidated net profit for the September quarter (Q2) of the fiscal year 2026-27 (FY27). This growth was achieved through an increase in testing revenues.
The company's net profit in Q2 FY27 amounted to 194 crore rupees, which is higher than the 152 crore rupees recorded during the same period last year. The main driver of this growth was the increase in sample volumes, which rose by 13.6% year-on-year to reach 28.8 million.
Furthermore, patient coverage in the network increased by 9% year-on-year, reaching 9 million in September, compared to 8.2 million in the same period the previous year. Consequently, the network's revenue increased by 19.6% year-on-year, reaching 874 crore rupees compared to 731 crore rupees in Q2 FY26.
Shankha Banerjee, CEO of DLPL, noted that there is a growing demand for high-complexity testing and specialized analyses, supported by increased awareness among doctors and patients. Operationally, the EBITDA margin increased by 25%, reaching 280 crore rupees from 224 crore rupees, and the EBITDA margin improved to 32.1% from 30.7%.
He also added that the company's future focus will be on expanding access to advanced diagnostics by strengthening capabilities in areas such as genomics, oncology, reproductive health, transplant diagnostics, and rare diseases.
As of September 30, 2026, DLPL, the largest provider of diagnostic services in India, operates 312 clinical laboratories, including the national reference laboratory in Delhi and regional reference laboratories in Kolkata, Bengaluru, and Mumbai. The network also includes 7,727 Patient Service Centers (PSC) and 13,935 Pickup Points (PUP), serving private patients, hospitals, healthcare professionals, and corporate clients.
DLPL's board of directors also approved an additional investment of up to 49.5 crore rupees in its wholly-owned subsidiary in Dubai, Dr Lal PathLabs FZCO, to meet its business and operational needs. In regulatory filings, DLPL indicated that this subsidiary will make further investments in its subsidiary Sunshine Healthcare Limited (SHL) in Ghana.
The results were announced during market trading. DLPL shares closed on the BSE on Wednesday 5.1% higher, at a price of 2,028.95 rupees per share.


